Latest Breaking News On - Panag pharma - Page 1 : vimarsana.com

Press release content from Accesswire. The AP news staff was not involved in its creation. Tetra Bio-Pharma Announces Granting of U.S. Patent for Treatment of Interstitial Cystitis April 15, 2021 GMT Approximately 12% of women may have early symptoms of Interstitial Cystitis OTTAWA, ON / ACCESSWIRE / April 15, 2021 / Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) ( TSX:TBP )( OTCQB:TBPMF )( FRA:JAM1 ), a biopharmaceutical pioneer in immunomodulator drug discovery and development announces the granting of a new patent from the United States Patent and Trademark Office for patent application number 16/190,450. This patent covers a method for the treatment of interstitial cystitis. ADVERTISEMENT Interstitial cystitis (IC), also known as bladder pain syndrome, is a chronic bladder health issue. According to the Interstitial Cystitis Association, approximately 4 to 12 million people in the U.S. are subject to IC, and approximately 90% of the IC patients are women. Epidemio

United statesPanag pharmaNatalie lerouxTrademark officeTetra bio pharma incIc centers for diseaseInterstitial cystitis associationHealth canadaRegulation services providerCanadian urological association journalTetra bio pharmaUnited states patentDisease controlGuy chamberlandஒன்றுபட்டது மாநிலங்களில்பனாக் பார்மா